Format

Send to

Choose Destination
Hum Vaccin Immunother. 2018;14(9):2128-2131. doi: 10.1080/21645515.2018.1430542. Epub 2018 May 1.

The global fight to develop antipoverty vaccines in the anti-vaccine era.

Hotez PJ1,2,3,4.

Author information

1
a Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology and Microbiology , National School of Tropical Medicine, Baylor College of Medicine , Houston , Texas , USA.
2
b Departmentof Biology , Baylor University , Waco , Texas , USA.
3
c James A Baker III Institute of Public Policy, Rice University , Houston , Texas , USA.
4
d Scowcroft Institute of International Affairs, Bush School of Government and Public Policy, Texas A&M University , College Station , Texas , USA.

Abstract

Antipoverty vaccines are the vaccines targeting a group of approximately 20 neglected tropical diseases (NTDs), as currently defined by the World Health Organization (WHO). The "antipoverty" moniker refers to the fact that NTDs trap populations in poverty due to their chronic and deleterious effects on child intellect and worker productivity. Therefore, NTD vaccines can be expected to promote both global health and economic advancement. Unfortunately, antipoverty vaccine development has lagged behind vaccines for major childhood infections and pandemic threats, despite evidence for their cost-effectiveness and cost-savings. Currently, the only licensed vaccines for NTDs include those for yellow fever, dengue, and rabies, although several other NTD vaccines for hookworm disease, schistosomiasis, leishmaniasis, and Zika and Ebola virus infections are in different stages of clinical development, while others are at the preclinical development stage. With the exception of the viral NTD vaccines there so far has been minimal industry interest in the antipoverty vaccines, leaving their development to a handful of non-profit product development partnerships. The major scientific and geopolitical hurdles to antipoverty vaccine development are discussed, including a rising antivaccine ("antivax") movement now entering highly populated low- and middle-income countries.

KEYWORDS:

Ebola; Zika; dengue; hookworm; schistosomiasis; trials for developing countries; tropical medicine; vaccinology; yellow fever

PMID:
29393710
PMCID:
PMC6183138
DOI:
10.1080/21645515.2018.1430542
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center